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Abstract 31 
Background: Well-known risk factors for Clostridium difficile infection (CDI) are exposure 32 
to antibiotics and gastric acid suppressants. Recent studies have provided some evidence of 33 
an association between hypovitaminosis D and the risk of CDI. Therefore, this meta-analysis 34 
aimed to pool all the existing evidence to investigate the association between 25-35 
hydroxyvitamin D (25[OH]D) and CDI. 36 
 37 
Methods: A systematic search was conducted in three databases (PubMed, Embase and Web 38 
of Sciences) for epidemiological studies that examined the association between mean 39 
25(OH)D concentrations and CDI as well as between 25(OH)D status and CDI severity or 40 
recurrence. 25(OH)D status was defined as “lower” or “higher” at a threshold concentration 41 
of <20 or ≥20ng/ml, respectively. Pooled effect sizes were computed using the inverse 42 
variance heterogeneity model of meta-analysis.  43 
 44 
Results: Eight publications (n = 4479 patients) were included in the meta-analysis. The mean 45 
concentration of 25(OH)D in patients with CDI was 3.54 ng/ml (95%CI: 0.39 to 6.89ng/ml) 46 
lower than in patients without CDI. Patients with lower 25(OH)D status had a higher odds 47 
(OR = 1.61; 95%CI: 1.02 to 2.53) of developing severe CDI compared to those with a higher 48 
25(OH)D status. No significant association was found between 25(OH)D status and CDI 49 
recurrence. 50 
 51 
Conclusion: The results of this meta-analysis suggest that lower mean concentrations of 52 
25(OH)D were associated with CDI. A lower 25(OH)D status increased the odds of severe 53 
CDI but not of CDI recurrence.  54 
 55 
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Clinical Relevancy Statement 58 
 Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated 59 
nosocomial diarrhea. Recent studies have reported contradictory evidence of hypovitaminosis 60 
D as a novel risk factor for CDI; therefore, the current meta-analysis was conducted to 61 
examine the association between 25-hydroxyvitamin D (25[OH]D) concentrations and CDI. 62 
The results of the pooled estimates reveal a lower mean concentration of 25(OH)D in subjects 63 
with CDI and an increased odds of severe CDI in patients with a lower 25(OH)D status. 64 
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Introduction 65 
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacillus and 66 
worldwide it is the main cause of infectious diarrhea in hospitalized patients. The incidence 67 
and severity of C. difficile infection (CDI) has increased in the last decades mainly due to the 68 
emergence of hypervirulent strains.1 It is estimated that the additional CDI attributable length 69 
of stay in acute-care facilities ranges from 2.8 to 6.4 days with an estimated cost per CDI case 70 
of up to US$ 15 397.2 The economic burden to the United States of America (USA) 71 
healthcare system attributable to CDI in 2008 was estimated at US$ 4.8 billion.3  72 
Traditionally, CDI has been associated with exposure to antimicrobials and gastric 73 
acid suppressant medications; however, a recent study has reported an association between 74 
higher concentrations of 25-hydroxyvitamin D (25[OH]D) and reduction in risk of CDI in 75 
patients with inflammatory bowel disease.4 Furthermore, Abdelfatah et al.5 found a protective 76 
effect against severe cases of CDI in patients with concentrations of 25(OH)D > 20ng/ml. In 77 
contrast, van der Wilden et al.6 did not find an association between 25(OH)D concentrations 78 
and CDI severity. 79 
Given the heavy burden on health systems imposed by CDI and the current 80 
contradictory evidence around 25(OH)D and CDI, a meta-analysis was conducted to assess 81 
the impact of 25(OH)D status on CDI.  82 
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Methods 83 
Search strategy and eligibility criteria 84 
 A systematic search with no language restrictions was undertaken in three medical 85 
and life sciences databases (PubMed, Embase and Web of Sciences) from their inception to 86 
August 2015. Search terms included were “Clostridium difficile” and “vitamin D”; the 87 
specific keywords and connectors for each database are listed in the Supplementary material.  88 
The inclusion of studies was restricted to published (full-text or conference abstracts) 89 
epidemiological studies in humans that reported concentrations of 25(OH)D in an extractable 90 
format. The studies were included if they reported mean 25(OH)D concentrations or data 91 
around the CDI related outcomes of severity or recurrence. Studies that reported findings in 92 
animal model were excluded. No exclusion criteria were considered for indirect methods to 93 
detect CDI cases such as ICD codes, as these have proven to be highly specific for CDI.7 94 
Similarly, no restrictions about CDI severity scores were considered as the majority of the 95 
score indices have a good sensitivity and specificity.8  96 
 97 
Study selection and data extraction  98 
Two researchers (LFK and KW) independently assessed all the citations by titles and 99 
abstracts followed by a full-text review of all potentially relevant studies. Data from the 100 
included studies were then independently extracted in a spreadsheet by the same two 101 
researchers. The recorded fields included study identifiers (authors, publication year); study 102 
characteristics (design, setting, inclusion criteria, sample size); mean 25(OH)D 103 
concentrations and outcome measurement (CDI, CDI severity, CDI recurrence). 25(OH)D 104 
status of “lower” or “higher” were defined based on concentrations <20 ng/ml and 105 
≥20ng/ml.9 The extracted data were then cross-checked by the two researchers and any 106 
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discrepancies during the selection of studies or data extraction were resolved through 107 
discussion and consensus.  108 
 109 
Statistical analyses 110 
The effect sizes for the difference in mean 25(OH)D concentrations across CDI diagnosis 111 
status and the odds ratios (OR) for the association between 25(OH)D status and CDI severity 112 
or CDI recurrence were pooled using the inverse variance heterogeneity (IVhet) model.10 113 
Statistical heterogeneity among studies was assessed by both the Cochran’s Q and I2 index; 114 
heterogeneity was defined as low (I2 < 25%), moderate (I2 = 26-50%) and high (I2 > 50%). 115 
While I 2 is the percentage of variability that is due to between-study heterogeneity, 1 – I 2 is 116 
the percentage of variability that is due to sampling error. The latter, it is affected by study 117 
size; thus, when the studies become very large, the sampling error tends to 0 and I 2 tends to 118 
1.11 Such heterogeneity may not be clinically relevant and studies with relatively large I 2 in 119 
this situation may still be usefully pooled if other measures such as Q or τ2 remain relatively 120 
small and clinically relevant heterogeneity is unlikely to be present. Additionally, the model 121 
used to pool effect sizes (IVhet model) takes account of the uncertainty due to heterogeneity 122 
and adjusts the confidence interval adequately,10 which does not happen with the random 123 
effects model, thus again justifying pooling in the face of heterogeneity documented using the 124 
I 2 index. 125 
The meta-analyses were conducted using MetaXL v3.0 (EpiGear International, 126 
Sunrise Beach, Australia).  127 
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Results 128 
Yield of search strategy 129 
The search strategy identified 147 records in the three databases after removal of 130 
duplicate records. Of these, 121 papers were excluded based on a review of title and abstract. 131 
Full texts of the remaining 26 studies were reviewed and 8 articles were selected and 132 
included in the final analyses (see Figure 1).  133 
 134 
Characteristics of included studies 135 
All the studies were conducted in healthcare settings in the USA. Half of the studies 136 
were conducted prospectively,4,6,12,13 one of which only enrolled patients with inflammatory 137 
bowel disease.4 Among the included studies, three reported 25(OH)D concentrations by C. 138 
difficile diagnosis outcome (infected versus non-infected).4,14,15 Three studies5,6,16 assessed 139 
the association between 25(OH)D status (<20 ng/ml versus ≥20 ng/ml) and CDI severity 140 
(mild versus severe). Finally, four studies5,12,13,16 examined the association between 25(OH)D 141 
status (<20 ng/ml versus ≥20 ng/ml) and CDI recurrence (see Table 1).  142 
 143 
Quantitative synthesis 144 
The pooled mean difference in 25(OH)D concentrations between patients with and 145 
without CDI was -3.54 ng/ml (95%CI: -6.89 to -0.39ng/ml) and thus mean 25(OH)D was 146 
lower in patients with CDI. Patients with lower 25(OH)D status were at higher odds of 147 
developing severe CDI compared to those with higher 25(OH)D status (OR = 1.61; 95%CI: 148 
1.02 to 2.53). No significant difference was found between patients with lower versus higher 149 
25(OH)D status in terms of CDI recurrence (OR = 1.26; 95%CI: 0.56 to 2.83; see Figure 2). 150 
Moderate (I2 = 48%) and high (I2 = 63%) heterogeneity was observed for the mean difference 151 
in 25(OH)D concentrations across CDI status group and the OR for 25(OH)D status and CDI 152 
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recurrence, respectively. No heterogeneity (I2 = 1%) more than expected due to chance was 153 
observed for the OR for 25(OH)D status and CDI severity. Despite the different degrees of 154 
heterogeneity, the confidence intervals under the IVhet model adequately account for the 155 
uncertainty due to heterogeneity and retain nominal coverage. Due to the limited number of 156 
studies included in each meta-analysis, visual inspection of the funnel plots was not possible 157 
to assess the presence of publication bias.  158 
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Discussion 159 
 Our findings provide some evidence that lower mean concentrations of 25(OH)D 160 
were present in subjects diagnosed with CDI and that CDI severity was associated with a 161 
lower 25(OH) status. Paradoxically, pooled estimates did not reveal an association between 162 
25(OH)D concentrations and CDI recurrence, one possible explanation for this finding may 163 
be differences in the duration of follow-up time used by the researchers. For instance, when 164 
CDI recurrence was defined as “within 30 days”, Arramraju et al.12 and Wang et al.13 found a 165 
significant association between lower 25(OH)D status and recurrence; however, when CDI 166 
recurrence was evaluated in a longer follow-up period of 56 and 90 days, Abdelfatah et al. 5 167 
and Wong et al. 16 did not find an association. We must point out however that study 168 
considerations may have had a role in this discrepancy. For example Wang et al13 categorized 169 
patients who died as a ‘non-resolution’ of CDI, which may have led to an overestimation of failure to 170 
resolve C. difficile, as the exact cause of mortality in each patient was unknown. Additionally, other 171 
factors such as exposure to certain antibiotics (cephalosporins, aminopenicillins and 172 
clindamycin), proton pump inhibitor use, increased patients age and number of previous 173 
admissions17 may have impacted on the CDI recurrence pooled estimate as controlling for 174 
these covariates was not possible. 175 
The findings align with those reported by Youssef and colleagues who described an 176 
association between 25(OH)D deficiency (< 20 ng/ml) and other hospital-associated 177 
infections such as bacterial sepsis and methicillin-resistant Staphylococcus aureus 178 
colonization.18  The findings are also in line with those hypothesized beneficial effect of 179 
vitamin D supplementation on the reduction of surgical site infections as well as catheter-180 
associated urinary tract infections.18 Additionally, ecological studies have reported an inverse 181 
relationship between ultraviolet B rays exposure (a major promotor of vitamin D synthesis) 182 
and CDI mortality19 or influenza cases complicated by pneumonia.20 Our findings therefore 183 
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add to the growing body of evidence identifying a potential role of lower 25(OH)D status in 184 
infectious disease susceptibility.  185 
Although the mechanisms by which 25(OH)D may act as an immunomodulator for 186 
CDI are not fully understood, possible explanations are available. Vitamin D plays a vital role 187 
in innate (nonspecific) immune response through the stimulation of nitric oxide,21 188 
cathelicidins22 and β-defensin 223 production in macrophage lysosomes and epithelial cells. 189 
Furthermore, vitamin D also modulates cell-mediated immunity via the differentiation of 190 
naïve T cells into regulatory CD4+ T lymphocytes.24 The immunomodulatory activity of 191 
vitamin D has also been described in patients with autoimmune disease (multiple sclerosis, 192 
systemic lupus erythematosus and rheumatoid arthritis) in which supplementation of vitamin 193 
D resulted in a reduction in disease severity.25-27 194 
This is the first meta-analysis that examines a potentially new risk factor for CDI; 195 
however, several limitations were noted that warrant future research. First, the strains of C. 196 
difficile ribotypes infecting individuals differ by country/region and certain C. difficile 197 
ribotypes are associated with different outcomes (e.g., recurrence, severity, mortality). The 198 
studies included here were all conducted in the northeast or midwest regions of the USA and 199 
C. difficile ribotypes was not taken into account. Second, due to the limited number of studies 200 
identified, subgroup analysis by the source of CDI (healthcare- versus community-acquired) 201 
was not possible. Finally, no studies were identified that examined the effect of 25(OH)D in 202 
asymptomatic C. difficile colonized individuals. Given that this group of people are a 203 
potential source of CDI and may contribute to the transmission of the pathogen, further 204 
epidemiological studies are required in order to investigate the role of 25(OH)D in this 205 
particular group of people. In view of the safety of vitamin D supplements and their potential 206 
to favorably influence the outcome or burden of CDI, we recommend the implementation of 207 
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randomized controlled trials to examine the effect of vitamin D supplementation in the 208 
reduction of CDI occurrence and CDI severity.   209 
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Table 1.- Characteristics of the included studies. 
Authors Setting Study design Inclusion criteria Patients’ mean 
(SD) age in years 
Sample size 
(25(OH)D <20 / 
≥20 ng/ml) 
Outcome measured 
Abdelfatah et al., 2015 5 Akron General Medical 
Center, Akron, OH, 
USA 
Case-control 
study (2007-2013) 
Hospitalized patients with 
positive C. difficile toxin assay 
and recorded 25(OH) D 
concentration 
68.7 (16.7) 271 (133 / 138) Severity of CDI and 
recurrence of CDI 
associated with 25(OH)D 
status  
Ananthakrishnan et al., 2014 4 Massachusetts General 
Hospital and Brigham 
and Women’s Hospital, 
Boston, MA, USA 
Cohort study Patients with inflammatory bowel 
disease and recorded plasma 
25(OH) D concentration 
60.5 (16.9) / 48.7 
(18.0) † 
3188 (20.4[12.8] / 
27.1[12.7])* 
Development of CDI 
associated with 25(OH)D 
concentrations 
Arramraju et al., 2010 12 New York Hospital 
Queens, Flushing, NY, 
USA 
Cohort study 
(2008-2009) 
Admitted patients with positive C. 
difficile toxin assay 
NR 62 (34 / 28) Resolution of CDI (no 
recurrence) associated 
with 25(OH)D status 
Quraishi et al., 2015 14 Massachusetts General 
Hospital and Brigham 
and Women’s Hospital, 
Boston, MA, USA 
Retrospective 
cohort study 
(1993-2006) 
Patients aged ≥18 years with 
documented 25(OH)D 
concentration prior admission. 
Patients without vitamin D 
supplementation or prior CDI. 
63 (18) 568 (17[10] / 
19[12])* 
Development of hospital-
acquired CDI associated 
with 25(OH)D 
concentrations 
Sahay and Ananthakrishnan 2014 15 Massachusetts General 
Hospital, Boston, MA, 
USA 
Case-control 
study (2010-2013) 
Patients with positive C. difficile 
toxin assay and recorded 
25(OH)D concentration 
62 (19) 116 (28.5[15.4] / 
33.8[12.8])* 
Community-acquired CDI 
associated with 25(OH)D 
concentrations 
van der Wilden et al., 2015 6 Massachusetts General 
Hospital, Boston, MA, 
USA 
Cohort study 
(2011-2013) 
Admitted patients with confirmed 
CDI 
62 (19) 100 (43 / 57) Severity of CDI associated 
with 25(OH)D status 
Wang et al., 2014 13 New York Hospital 
Queens, Flushing, NY, 
USA 
Cohort study 
(2008-2009) 
Hospitalized patients with 
positive C. difficile toxin assay 
75 (17) 62 (38 / 24) Mortality and CDI 
recurrence associated with 
25(OH)D status 
Wong et al., 2015 16 Akron General Medical 
Center, Akron, OH, 
USA 
Case-control 
study (2007-2012) 
Hospitalized patients diagnosed 
with CDI and recorded 25(OH)D 
concentration within 3 months of 
CDI 
68 (15.7) / 71 
(4.4) ‡ 
112 (56 / 56) Severity of CDI and 
recurrence of CDI 
associated with 25(OH)D 
status 
CDI: Clostridium difficile infection; SD: standard deviation; NR: not reported 
† mean (standard deviation) age for patients with CDI / mean (standard deviation) age for patients without CDI 
‡ mean (standard deviation) age for patients with 25(OH)D < 20ng/ml / mean (standard deviation) age for patients with 25(OH)D ≥ 20ng/ml 
* mean[standard deviation] of the patients with CDI / mean[standard deviation] of the patients without CDI 
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Figure 1.- Preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
flow-diagram. 
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A 
B
C
Figure 2.- Forest plots depicting (A) the weighted mean difference  in 25(OH)D 
concentrations across CDI status groups;  (B) the odds ratio for 25(OH)D status and CDI 
severity; and (C) the odds ratios for 25(OH)D status and CDI recurrence. 
 
